NRG-HN001

Randomized Phase II AND Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Contact phone
Clinical Trials Office – 517.364.9400
Principal investigator
Gordan Srkalovic
Trial Category
Cancer
Trial SubCategory
Nasopharynx Carcinoma